UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors

CPT: pharmacometrics and systems pharmacology, 2021-05, Vol.10 (5), p.455-466

2021

Volltextzugriff (PDF)

Effect of Enzyme Inhibition on Perampanel Pharmacokinetics: Why Study Design Matters

Epilepsy research, 2017-08, Vol.134, p.41-48

2017

Volltextzugriff (PDF)

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.777-791

2019

Volltextzugriff (PDF)

Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

Clinical and translational science, 2018-09, Vol.11 (5), p.477-486

2018

Volltextzugriff (PDF)

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

CPT: pharmacometrics and systems pharmacology, 2018-03, Vol.7 (3), p.135-146

2018

Volltextzugriff (PDF)

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

CPT: pharmacometrics and systems pharmacology, 2023-04, Vol.12 (4), p.444-461

2023

Volltextzugriff (PDF)

Eribulin shows high concentration and long retention in xenograft tumor tissues

Cancer chemotherapy and pharmacology, 2017-08, Vol.80 (2), p.377-384

2017

Volltextzugriff (PDF)

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges

CPT: pharmacometrics and systems pharmacology, 2020-01, Vol.9 (1), p.5-20

2020

Volltextzugriff (PDF)

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

CPT: pharmacometrics and systems pharmacology, 2019-09, Vol.8 (9), p.685-695

2019

Volltextzugriff (PDF)

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

International journal of pharmaceutics, 2013-02, Vol.443 (1-2), p.9-16

2013

Volltextzugriff (PDF)

Physiological, Pharmacokinetic, and Pharmacodynamic Changes in Space

Journal of clinical pharmacology, 2004-08, Vol.44 (8), p.837-853

2004

Volltextzugriff (PDF)

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

Xenobiotica, 2011-04, Vol.41 (4), p.320-326

2011

Volltextzugriff (PDF)

Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents

Expert review of anti-infective therapy, 2005-06, Vol.3 (3), p.361-373

2005

Volltextzugriff (PDF)

A Transcellular Assay to Assess the P-gp Inhibition in Early Stage of Drug Development

Drug metabolism letters, 2013-07, Vol.6 (4), p.285-291

2013

Volltextzugriff (PDF)

Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model

Bioorganic & medicinal chemistry letters, 2011-03, Vol.21 (6), p.1639-1643

2011

Volltextzugriff (PDF)

Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.229-237

2012

Volltextzugriff (PDF)

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

The Lancet infectious diseases, 2021-08, Vol.21 (8), p.1129-1140

2021

Volltextzugriff (PDF)

Perampanel and pregnancy

Epilepsia (Copenhagen), 2021-03, Vol.62 (3), p.698-708

2021

Volltextzugriff (PDF)

Changes in perampanel levels during de‐induction: Simulations following carbamazepine discontinuation

Acta neurologica Scandinavica, 2020-08, Vol.142 (2), p.131-138

2020

Volltextzugriff (PDF)

Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers

Journal of clinical pharmacology, 2005-07, Vol.45 (7), p.822-831

2005

Volltextzugriff (PDF)

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial

Alzheimer disease and associated disorders, 2022-07, Vol.36 (3), p.200-207

2022

Volltextzugriff (PDF)

Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers

Antimicrobial agents and chemotherapy, 2021-03, Vol.65 (4)

2021

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

British journal of clinical pharmacology, 2018-05, Vol.84 (5), p.952-960

2018

Volltextzugriff (PDF)

Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase

Journal of medicinal chemistry, 2014-03, Vol.57 (6), p.2582-2588

2014

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Aktive Filter

KollektionPublisher website

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(46)
Dissertationen
(1)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors

Effect of Enzyme Inhibition on Perampanel Pharmacokinetics: Why Study Design Matters

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

Eribulin shows high concentration and long retention in xenograft tumor tissues

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

Physiological, Pharmacokinetic, and Pharmacodynamic Changes in Space

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents

A Transcellular Assay to Assess the P-gp Inhibition in Early Stage of Drug Development

Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model

Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

Perampanel and pregnancy

Changes in perampanel levels during de‐induction: Simulations following carbamazepine discontinuation

Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial

Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase

Aktive Filter

Suchergebnisse filtern